Drug Science publish regular articles that analyse developments in drug science and policy to highlight areas of improvement based on evidence

Get Project Twenty21 Updates via Email Last month saw Drug Science’s festival debut as we took up a stand alongside our medical cannabis friends from PLEA, Medcan Support and MedcannID at the incredible Product Earth Expo. We gave away hundreds of stickers, badges and posters to help spread the word about medical…

Get Project Twenty21 Updates via Email It's been another busy month at Project Twenty21, with new patient numbers continuing to grow month-on-month, as you will see from our July data below. Last month, we spoke to Leafie about the progress of the project and what we're learning from the data -…

In this update, find out what GPs think about medical cannabis as we celebrate 1000 patients joining Project Twenty21. We share updates on the project, including new clinics and data insights, as well as initiatives working to improve medical cannabis in the UK. We also announce new events related to the…

Ketamine, 2-(2-chlorophenyl)-2-(methylamino)-cyclohexan-1-one, is a dissociative sedative with analgesic and anaesthetic properties, now being investigated as an antidepressant, alone and as part of ketamine-assisted therapy. Discovered in 1962 by Calvin L. Stevens, and first tested on humans in 1964, ketamine was approved for medical use by the USA in 1970 and remains…